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Summary
For more than seven decades, antibiotics and chemotherapeutics 
have been used successfully to treat and prevent infectious diseases, 
extensively changing the prognosis of severe infections and helping 
to improve quality of life. In the last two decades, the key role of 
the intestinal microbiota (IM) in basic vital functions such as diges-
tion, protection against pathogens, and maintenance of immune and 
metabolic homeostasis has been recognized. Antibiotics do not selec-
tively attack pathogenic bacteria. They have an effect on the normal 
microflora and can lead to imbalance inside the body (dysbacteriosis) 
and the development of opportunistic infections. Taking a probiotic 
during antibiotic treatment is one of the approaches to prevent antibi-
otic-associated diarrhea and other adverse effects of antibiotics when 
their use is necessary. In the present practical monitoring we want to 
share our results from the application of Sinquanon® to neutralize the 
negative effect of antibiotic treatment on the microbiome.
Introduction
In daily otorhinolaryngological practice in the 
treatment of bacterial infections, the role of antibi-
otics is indispensable. However, when dealing with 
pathogenic bacteria, they have detrimental effects 
on the microflora, which can be clinically manifest-
ed both in the short and long term. Increasing sci-
entific evidence supports the relationship between 
impaired gastrointestinal microflora and diseases 
outside the gastrointestinal tract, which may find 
clinical manifestation years after antibiotic admin-
istration. Intestinal dysbiosis is characterized by 
significant loss of beneficial bacteria, excessive 
growth of potential pathogens, loss of microbial 
diversity and reduced stability. One of the most 
common complications that immediately follow 
antibiotic therapy is antibiotic-associated diarrhea, 
which can affect more than 30% of patients. Irrita-
ble bowel syndrome is another complication that 
can occur immediately after the course of antibiot-
ics and months, even years after. 
We must emphasize the fact that probiotic products 
are not the same! Most of the existing probiotics 
are not closely specialized, so they cannot fully 
protect the intestinal microbiome during AB thera-
py, resulting in a number of adverse side effects of 
the antibiotic. Sinquanon® is a specialized probiotic 
designed to help all patients with AB treatment – 
regardless of the type of AB taken and whether the 
patient has had side effects from antibiotics in the 
past.
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Intake of Sinquanon® helps to restore the micro-
bial diversity and amount lost during antibiotic 
treatment as quickly and completely as possible, 
restoring the microbiome to its initial levels, thus 
reducing the occurrence of antibiotic-associated 
diarrhea and the onset of pain/flatulence.
Material and methods
Our practical clinical monitoring was conducted 
in the ENT Slinic at the ENT Clinic at the Uni-
versity First Multi-Profile Hospital for Active 
Treatment-Sofia EAD, for the period 01.06.2020 – 
31.07.2020 and covered 42 patients aged between 
11 and 89 years with diagnoses: Abscessus periton-
sillaris, Tonssilitis lacunaris, Epistaxis and Otitis 
media serosa acuta. For the purposes of the study, 
we compiled a protocol for Practical Clinical Mon-
itoring. Of our patients, 8 were on parenteral and 
34 on oral therapy, and in 34 of the cases the anti-
biotic used was Amoxiclav 625, in 2 cases we used 
Unasyn and in 6 cases – Ceftriaxone. 
Pre-hospital therapy was performed in 8 patients. 
No adverse effects of AB treatment were reported 
in 38 of 42 patients. Only 4 had side effects, with 
two experiencing abdominal pain and antibiotic 
associated diarrhea (AAD) on day 3, and had start-
ed taking Sinquanon® after the onset of complaints. 
Two patients showed AAD on day 2. From these 
data, we concluded that Sinquanon® provided a 
90% reduction in the side effects of the applied AB 
treatment. 
In a control group of 16 patients, for the same 
period of time, aged between 19 and 68 years, 
4 of them showed symptoms of abdominal pain 
and AAD on the second day of antibiotic therapy. 
Flatulence was reported in 2 patients in the group 
on day 3. 
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a specialized probiotic designed to help all patients with AB treatment - regardless of the type of 
AB taken and whether the patient has had side effects from antibiotics in the past. 
Intake of Sinquanon® helps to restore the microbial diversity and amount lost during antibiotic 
treatment as quickly and completely as possible, restoring the microbiome to its initial levels, 
thus reducing the occurrence of antibiotic-associated diarrhea and the onset of pain/flatulence. 
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Abscessus per tonsillaris, Ton sil tis lacunaris, Epistaxis and Otitis media s rosa acuta. For the 
purposes of the study, we compiled a pro ocol for Practical Clinical Monitoring. Of our patients, 
8 were on pa enteral and 34 on oral therapy, and in 34 of the cases the antibiotic used was 
Amoxiclav 625, n 2 cases we used Unasyn and in 6 cases - Ceftriaxone.  
Fig 1. Alignment of  of patients according to the type of antibiotic therapy 
 
Pre-hospital therapy was performed in 8 patients. No adverse effects of AB treatment were 
reported in 38 of 42 patients. Only 4 had side effects, with two experiencing abdominal pain and 
antibiotic associated diarrhea (AAD) on day 3, and had started taking Sinquanon® after the onset 
of complaints. Two patients showed AAD on day 2. From these data, we concluded that 
Sinquanon® provided a 90% reduction in the side effects of the applied AB treatment.  
 

















In a control group of 16 patients, for the same period of time, aged between 19 and 68 years, 4 of 
them showed symptoms of abdominal pain and AAD on the second day of antibiotic therapy. 
Flatulence was reported in 2 patients in the group on day 3.  
Discussion 
Sinquanon® is a specialized probiotic for antibiotic therapy, which promptly helps to restore to 
the greatest extent the lost microbial count of beneficial bacteria in the intestinal microbiota, 
restores lost biodiversity in the intestinal ecosystem, helps the reproduction of beneficial bacteria 
and supplies additional B vitamins. It contains a mixture of 14 specially selected probiotic 
strains, in a daily dose of 100 billion living cells. It has been proven that the action of probiotics 
depends on the dose - the higher it is, the better the effect. The high number of beneficial bacteria 
collected in a daily dose makes Sinquanon® a specialized probiotic to be used with antibiotic. 
Secondly, what distinguishes it is the large strain diversity of beneficial bacteria contained in it, 
specially selected and fully tailored to the needs of patients on antibiotic treatment. It is 
important to take a probiotic product containing strains that will survive during AB therapy. 
Sinquanon® contains strains with natural resistance against various AB. The probiotic strains in 
Sinquanon® are of the genus Lactobacillus, Bifidobacterium, Saccharomyces, and spore-forming 
bacilli. They are characterized by a high rate of division and high natural resistance to 
antibiotics. The probiotic contains two of the best studied worldwide and highly recommended 
by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the 
World Gastroenterology Organization probiotic strains for the prevention of antibiotic- 
associated diarrhea - Lactobacillus rhamnosus GG and Saccharomyces boulardii. Sinquanon® 
also contains a special probiotic strain Bacillus coagulans, which turns into a spore under adverse 
conditions. This makes it extremely resistant to harmful influences, for example in antibiotic 
therapy. It also increases the population of beneficial bacteria in the gut. The presence of so 
many different strains contributes to their synergistic action. During antibiotic treatment, the 
normal synthesis of B vitamins decreases, so in addition to the probiotic blend, Sinquanon® also 
contains a complex of six B vitamins in the recommended daily doses. It also contains a patented 
prebiotic blend, specially created for the needs of the 14 probiotic strains included in its 
composition. It includes three types of oligosaccharides that are not degradable by the human 
body, which serve as food for probiotic strains and beneficial bacteria that live normally in the 
gastrointestinal tract. Prebiotics help strains to divide even faster. The Sinquanon® capsule is 
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Fig 1. Alignment of   of  patients ccording to the typ  of  antibiotic therapy
Fig 2. Clinical efficacy of  Sinquanon® in patients on AB therapy
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Discussion
Sinquanon® is a specialized probiotic for antibiotic 
therapy, which promptly helps to restore to the 
greatest extent the lost microbial count of benefi-
cial bacteria in the intestinal microbiota, restores 
lost biodiversity in the intestinal ecosystem, helps 
the reproduction of beneficial bacteria and supplies 
additional B vitamins. It contains a mixture of 14 
specially selected probiotic strains, in a daily dose 
of 100 billion living cells. It has been proven that 
the action of probiotics depends on the dose – the 
higher it is, the better the effect. The high number 
of beneficial bacteria collected in a daily dose 
makes Sinquanon® a specialized probiotic to be 
used with antibiotic. Secondly, what distinguishes 
it is the large strain diversity of beneficial bacteria 
contained in it, specially selected and fully tailored 
to the needs of patients on antibiotic treatment. It 
is important to take a probiotic product containing 
strains that will survive during AB therapy. Sin-
quanon® contains strains with natural resistance 
against various AB. The probiotic strains in Sin-
quanon® are of the genus Lactobacillus, Bifidobac-
terium, Saccharomyces, and spore-forming bacilli. 
They are characterized by a high rate of division 
and high natural resistance to antibiotics. The pro-
biotic contains two of the best studied worldwide 
and highly recommended by the European Society 
for Paediatric Gastroenterology, Hepatology and 
Nutrition and the World Gastroenterology Organi-
zation probiotic strains for the prevention of anti-
biotic- associated diarrhea – Lactobacillus rhamno-
sus GG and Saccharomyces boulardii. Sinquanon® 
also contains a special probiotic strain Bacillus 
coagulans, which turns into a spore under adverse 
conditions. This makes it extremely resistant to 
harmful influences, for example in antibiotic ther-
apy. It also increases the population of beneficial 
bacteria in the gut. The presence of so many dif-
ferent strains contributes to their synergistic action. 
During antibiotic treatment, the normal synthesis 
of B vitamins decreases, so in addition to the pro-
biotic blend, Sinquanon® also contains a complex 
of six B vitamins in the recommended daily doses. 
It also contains a patented prebiotic blend, special-
ly created for the needs of the 14 probiotic strains 
included in its composition. It includes three types 
of oligosaccharides that are not degradable by the 
human body, which serve as food for probiotic 
strains and beneficial bacteria that live normally in 
the gastrointestinal tract. Prebiotics help strains to 
divide even faster. The Sinquanon® capsule is gas-
tro-resistant, which means that it passes through the 
aggressive stomach acid and dissolves in the small 
intestine. As a result of this, it delivers live probiot-
ic bacteria to the right place, where they have their 
beneficial effect. 
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